Last edition
News about "Immunology Drug Development"
Biogen Closes Acquisition of RayThera
Biogen completes the acquisition of RayThera Inc., adding a phase 1 lead program to strengthen its pipeline and advance innovative therapeutic development.
Immunology Drug Development | 07/08/2026 | By News Bureau
Johnson & Johnson Secures FDA Approval for Icotyde, First Oral IL-23 Inhibitor for Psoriasis
FDA approves Johnson & Johnson’s Icotyde, a first-in-class oral IL-23 receptor antagonist, offering a once-daily treatment option for moderate-to-severe plaque psoriasis in adults and adolescents.
Immunology Drug Development | 20/03/2026 | By News Bureau | 360
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy